The global discourse surrounding the management of Attention-Deficit Hyperactivity Disorder (ADHD) frequently centers on methylphenidate, the active pharmacological agent in medications like Ritalin. As awareness of neurological health grows, patients and researchers alike are seeking to understand how this stimulant is classified, regulated, and integrated into treatment programs across diverse jurisdictions, including the UK, Germany, […]
Bulgaria has become an important point of discussion in Europe’s growing conversation around MDMA, harm reduction, and responsible psychedelic use. Known globally as “Ecstasy” or “Molly,” 3,4-methylenedioxymethamphetamine (MDMA) has a complex profile—it is both a stimulant and an empathogen, capable of enhancing mood, empathy, and sensory perception. However, without proper knowledge and precautions, its misuse […]